Nourianz (Istradefylline) Patent Expiration, LOE Window & CMS Spending

Nourianz (Istradefylline) by Kyowa Kirin: FDA Orange Book LOE 2028-01-28, 0 AB generics, $52.7M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorKyowa Kirin
FDA Application & PathwayN022075 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-01-28
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$52.7M
2024 Medicare Part D Spend$50.7M
2024 Medicaid Spend$1.9M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.2% 2-yr change)